Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study
Pretreatment H&E-derived pathomics, integrated with baseline clinical biomarkers, enable accurate prediction of CIP risk in locally advanced or metastatic NSCLC. This framework supports proactive surveillance and individualized immune checkpoint inhibitor (ICI) strategies and provides a scalable route to decode TIME-relevant states from routine pathology.
Authors
- Yibo Shan (ORCID: https://orcid.org/0000-0003-1460-4609)
- Juan Liu (ORCID: https://orcid.org/0000-0003-3568-0889)
- Yi Lu (ORCID: https://orcid.org/0000-0003-1221-6709)
- Fei Sun (ORCID: https://orcid.org/0000-0002-6280-2063)
- Y. Zhang
- Yiwei Fan
- Hongcan Shi
- Lintao Guo
- Jianwei Zhu
- Qi Wang
- Jie Lei
- Shichun Lu
- Wenxuan Chen
- Lei Yuan
- Wenlong Yang
Institutions
- The First People’s Hospital of Lianyungang (CN)
- Northern Jiangsu People's Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Changzhou No.2 People's Hospital (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fimmu.2026.1792179
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00